

Research Paper



Evaluation of treatment modalities for pure asthenospermia regarding changes in seminal fluid parameters

Dr. Nafea Taha Salih^{1*}, Dr. Gailan Adil Saeed²

¹M.B.CH.B. \ F.I.C.M.S. \ (URO) – Urology Iraqi Ministry of Health, Kirkuk Health Directorate, Kirkuk Teaching Hospital, Kirkuk, Iraq.

²M.B.CH.B. \ F.I.C.M.S. \ (URO) – Urology Iraqi Ministry of Health, Kirkuk Health Directorate, Azadi Teaching Hospital, Kirkuk, Iraq.

Article Info

Article History:

Received: 03 April 2023

Revised: 08 June 2023

Accepted: 16 June 2023

Published: 29 July 2023

Keywords:

Asthenospermia


Treatment Modalities

Seminal Fluid

Subclinical Varicocele

Sperm Motility

Varicocele



ABSTRACT

Background: Asthenospermia is one of the most frequent results seen in semen fluid analysis among infertile males. Even with broad diagnostic workup, the cause is often, sort of, unclear and that leads to ongoing debate about what the best management should actually be.

Objective: To assess how well two treatment options work-subinguinal varicocelelectomy and oral L-carnitine intake-in men who have pure asthenospermia, by looking at how their seminal fluid measurements change over time.

Methods: This prospective study was carried out at AL-Yarmouk Teaching Hospital, Urology Department, Iraq between August 2021 and April 2022. A total of 118 infertile men with documented pure asthenospermia (verified by at least 2 initial semen fluid tests) were included. Participants were divided into a surgical group (n = 71, meaning clinically detected or even subclinical varicoceles) versus a medical group (n = 47, meaning no visible varicoceles). The surgical group received a subinguinal varicocelelectomy, while the medical group was given oral L-carnitine 1 g/day. After that, all patients were followed for roughly 6 to 12 months using repeated seminal fluid assessments. Any adverse effects related to treatment were noted during the whole follow up. **RESULTS** In the surgical arm, there were 26 patients with grade 1, 23 with grade 2, and 12 with grade 3 varicoceles, plus 10 additional men with subclinical varicoceles. In the medical arm, 32 patients had no varicoceles, and 15 had subclinical varicoceles. After varicocelelectomy there was a statistically meaningful improvement in total sperm motility, and the extent of gain seemed to track steadily with the varicocele grade. Men with subclinical varicoceles did not show a statistically significant improvement after the operation. L-carnitine supplementation also led to mild or moderate gains in sperm motility, but these changes still did not reach statistical significance, and importantly no important adverse events were recorded.

Conclusions: Subinguinal varicocelectomy should be considered the more suitable option for pure asthenospermia in men who have clinically detectable varicoceles, especially because higher-grade disease tends to produce better results. L-carnitine, as a monotherapy, looks safe as an adjunct but it is not enough on its own to restore or normalize sperm motility measures.

Corresponding Author:

Dr. Nafea Taha Salih

M.B.CH.B. \ F.I.C.M.S. \ (URO) – Urology Iraqi Ministry of Health, Kirkuk Health Directorate, Kirkuk Teaching Hospital, Kirkuk, Iraq.

Email: Nafeataha0@gmail.com

Copyright © 2023 The Author(s). This is an open access article distributed under the Creative Commons Attribution License, (<http://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Asthenospermia, another name for asthenozoospermia, is an infertility disorder in which a person's sperm motility-or sperm's capacity to move-is diminished. The likelihood of the sperm attaching to the egg within the female reproductive system is decreased by decreased sperm motility. One of the most frequent reasons for male-factor infertility as, in addition to oligospermia (low sperm count), is asthenospermia [1], [2].

Reduced sperm motility is a symptom of the infertility disorder asthenospermia. Sperm motility refers to the sperm's capacity to "swim" its way to the egg inside the female reproductive system. In the condition known as asthenozoospermia, there is no sperm motility [3], [4].

Along with oligospermia and low sperm count, asthenospermia is one of the most frequent reasons of infertility in men and can drastically lower the likelihood of getting pregnant [5]. Under forty percent motility of sperm or less below 32% progressive motility is considered asthenospermia. Sperm that exhibits progressive motility travels in broad arcs or straight lines [6].

Asthenospermia, also known as teratospermia, is frequently accompanied with oligospermia and is commonly present in patients. Additionally, asthenospermia patients typically have greater levels of sperm DNA fragmentation [7].

Male infertility is directly impacted by asthenospermia, which also greatly lowers the likelihood of pregnancy. Fertilization chances are considerably diminished if sperm cannot get to the egg in the female's reproductive system [8], [9].

Sperm motility is an essential prerequisite for establishing natural fertilization as well as pregnancy because sperm must travel a considerable distance through the fallopian tube in order to connect with and fertilize the egg. Therefore, asthenospermia may be detrimental to male fertility [10], [11].

Inflammatory conditions affecting the sperm duct, which is varicocele, immunologic factors, abnormalities in the genome, along with lifestyle and environmental variables, are only a few of the numerous probable causes of asthenospermia. Diagnose asthenospermia and learn about the general sperm concentration, morphology, and motility with a semen analysis test (SA) [12], [13].

A smart initial step in treating asthenospermia is to adopt better lifestyle practices, including giving up smoking, consuming less alcohol, and eating a balanced diet. Asthenospermia-related infertility has also been treated using assisted reproductive technology (ART), such as intrauterine insemination (IUI), in vitro fertilization (IVF), and intracytoplasmic sperm injection (ICSI) [14], [15]. This paper aims to Evaluate of treatment Modalities for pure Asthenospermia regarding changes in seminal fluid parameters.

2. METHODOLOGY

This is a prospective study conducted at Al-Yarmouk Teaching Hospital /urology department from 23rd August 2021 to 18th April 2022. 118 male patients were included.

2.1. Inclusion Criteria

All patients were married and overall healthy; their ages ranged from 20- 39 years with primary or secondary infertility for more than one year of unprotected intercourse with pure or isolated asthenospermia.

2.2. Exclusion Criteria

Normal semen parameters, patients with azoospermia, oligospermia, teratospermia, low ejaculatory volume, abnormal hormonal profile, Antisperm antibody test +ve, significant genital infection, and occupational exposure to heat or chemicals

2.3. Patients Were Divided into Two Groups

In surgical arm patients with all grades of varicocele, including the clinical palpable varicoceles (G1-G3) and subclinical (detected by Doppler U/S), with pure asthenospermia.

In medical arm patients either, with or without subclinical varicoceles (determined by scrotal Doppler U/S) with no other identifiable risk factors or idiopathic.

All patients were clinically assessed by history, physical examination, and seminal fluid analysis. All patients underwent two or more seminal fluid analyses before intervention as a baseline with a constant number of days of sexual abstinence, 3-5 days.

We depend on total sperm progressive motility (grade A +grade B) as a standard for comparison.

2.4. According to The Treatment Method, Patients with Asthenospermia Were Divided into Two Groups

- **Surgical Arm:** Was subjected to subinguinal varicocelectomy (for clinical and subclinical varicoceles). medical arm" L-carnitine group" (patients without or with subclinical varicoceles) were subjected to medical treatment with L-carnitine supplementation 1gm /day for at least six months and instructed to avoid using other relevant medications during the treatment period.

2.5. Outcome Measures

Were changes from the mean baseline level of semen parameters (sperm motility) and the occurrence of adverse events of treatment during the 6- 12 –months period of follow-up after treatment?

2.6. Follow Up

For both groups, follow-up was at 3,6,12 months after the intervention. Changes in Seminal fluid analyses at 3,6,12 months were documented. All participants were assessed for adverse effects of treatment throughout the study period.

2.7. Surgical Arm

Patients were evaluated for Varicocele recurrence. Hydrocele formation and Changes in testicular size.

2.8. Medical Arm

Patients were evaluated for side effects of medical treatment and any changes in varicocele grade. Changes in seminal fluid parameters (motility) were also correlated with the grade of varicocele in the surgical arm, and the impact of treatment on patients with subclinical varicocele in both groups was also studied.

Statistical method used in our study was according to the Statistical Packages for social scientists (SPSS) version 20 program for quantitative data, we used T-test, and for qualitative data, we used the Chi-square test.

3. RESULTS AND DISCUSSION

Table 1. Preliminary Data of the Patients

	Surgical Group Varicocelectomy (N=71)		Medical Group L-Carnitine (N=47)		X2; Def.; P Value	
	No	%	No	%		
Age (years)	Mean±SD (Range)		28.4±5.7 (17-40)		0.403	
	29.3±5.7 (17-40)					
Varicocele Grade	G1	26	36.6	-	-	-
	G2	23	32.4	-	-	-
	G3	12	16.9	-	-	-
	Subclinical	10	14.1	15	31.9	
	Without	-	-	32	68.1	
	Total number	71	100	47	100	

Table 2. Baseline Levels of Mean Motility Status in Each Group

Group	Varicocele Grade	Mean Motility Status%				X2; D. F.; P Value
		0---19%		20---39%		
No	No	No	%	No	%	
Surgical Varicocelectomy (n=71)	G1	12	46.2	14	53.8	0.428
	G2	7	30.4	16	69.6	
	G3	5	41.7	7	58.3	
	Subclinical	6	60.0	4	40.0	
Medical L- Carnitine (n=47)	Subclinical	9	60.0	6	40.0	0.809
	Without	18	56.3	14	43.7	




Figure 1. Baseline Levels of Mean Sperms Motility Status in the Surgical Group




Figure 2. Baseline Levels of Mean Sperms Motility Status in the Medical Group

Table 3. Changes in Sperms Motility after Varicocelectomy Treatment

Surgical Group Varicocelectomy (N=71)		Varicocele Grade						P Value	
		G1 (N=26)		G2 (N=23)		G3 (N=12)		Subclinical (N=10)	
Improvement	19	73.1	19	82.6	9	75.0	4	40.0	0.093
Good	4	15.4	6	26.1	8	66.7	2	20.0	0.006*
Minimal	15	57.7	13	56.5	1	8.3	2	20.0	
No improvement	7	26.9	4	17.4	3	25.0	6	60.0	

Table 4. Changes in Sperms Motility after L-Carnitine Treatment

Medical Group (L-Carnitine) (N=47)	No Subclinical Varicocele (N=32)		Subclinical Varicocele (N=15)		X ² ; D. F.; P Value
	No	%	No	%	
Improvement	13	40.6	6	40.0	0.968
Good	4	12.5	1	6.7	0.516
Minimal	9	28.1	5	33.3	
No improvement	19	59.4	9	60.0	-




Figure 3. Sperms Motility Status in Surgical Group after Varicocelectomy




Figure 4. Sperms Motility Status in L-Carnitine Group after Medical Treatment

Table 5. Changes in Sperms Motility after Treatment in Each Group

Group	Varicocele Grade	Mean Motility Status%						P Value
		0---19%		20---39%		=>40%		
		No	%	No	%	No	%	
Surgical Varicocelectomy (n=71)	G1	7	26.9	15	57.6	4	15.5	0.010*
	G2	4	17.4	13	56.5	6	26.1	
	G3	3	25.0	1	8.3	8	66.7	
	Subclinical	6	60.0	2	20.0	2	20.0	
Medical L- Carnitine (n=47)	Subclinical	9	60.0	5	33.3	1	6.7	0.811
	Without	19	59.3	9	28.2	4	12.5	

Table 6. Changes in Sperms Motility According to Treatment Modality

	Surgical Group Varicocelectomy(N=71)		Medical Group L- Carnitine(N=47)		X2; Def.; P Value
	No	%	No	%	
Improvement;	51	71.8	19	40.3	0.0007*
Good	20	28.2	5	10.5	
Minimal	31	43.6	14	29.8	
No improvement	20	28.2	28	59.7	0.317

Table 7. Adverse Effects/Complications of Each Treatment Modality

Side Effects	Surgical Group Varicocelectomy(N=71)		Medical Group L- Carnitine(N=47)	
	No	%	No	%
Hydrocele	5	7.0	-	-
Varicocele recurrence	3	4.2	-	-
Testicular atrophy	1	1.4	-	-
GIT side effect	-	-	7	14.9
Insomnia	-	-	1	2.1
Headache	-	-	9	19.1
Wound infection	7	9.8	-	-
Prolonged testicular pain	3	4.2	-	-
Allergy to L-carnitine	-	-	1	2.1

3.1. Discussion

Asthenospermia is one of the most common findings in the seminal fluid analysis of patients with infertility. Isolated asthenospermia refers to low levels of motility or forwards progression or both. It may be caused by overt causes, or it may be idiopathic, so in spite of a full diagnostic workup, the causes of asthenospermia are not always clear. Accordingly, there are a lot of controversies about the best treatment for such conditions, but in general, the best results are achieved when treatment is directed toward an overt cause. Our study included two groups of patients, those with varicocele (with its different grades) and those patients with no overt identifiable cause [16] because these two groups are the commonest groups of patients with asthenospermia seen in our clinical practice. Varicocele is the most common surgically correctable abnormality found in infertile men and may be responsible for sperm motility defects as well as defects in sperm count and shape. An important subgroup of patients with this condition is those with subclinical varicoceles that are not palpable or suspected on physical examination but are diagnosed radiologically [17]. The need to treat subclinical varicoceles and the direct effect these vascular lesions have on male infertility have been debated. Treatment modalities used in our study were logically varicolectomy for those patients with clinical varicocele (as a surgical problem), while those patients with no overt cause for their Asthenospermia were treated empirically by medical treatment. From a wide spectrum of drugs used as empirical treatment for Asthenospermia (vitamins, trace elements, hormones. etc.) [18], we decided to use L-carnitine because of its promising effects on sperms motility as mentioned in many published articles, and because of its relatively recent availability in our pharmacies.

As we needed to test these two treatment modalities on a group of patients with the same characteristics (for a better-controlled comparison), we designed our study to put patients with subclinical varicocele into the two arms of treatment [19]. In our study, Patients in the surgical arm (clinical varicocele group) treated by varicolectomy show significant improvement in sperm motility during the follow-up period, and at the same time, patients with subclinical varicoceles who were treated with varicolectomy show no such significant improvement. Good improvement (>40%) was obvious in patients with G2 and G3 varicocele, while minimal improvement (20%-40%) was seen more in patients with G1 and G2 varicocele, and no improvement in sperm motility was the commonest finding in subclinical varicoceles group. Many studies have demonstrated that subclinical varicoceles have no impact on fertility and that repair of subclinical varicoceles does not improve fertility rates. The result in our study goes with most of previous studies in that varicolectomy for clinically detected varicoceles significantly improves sperm motility. In the other hand, the varicolectomy for subclinical varicoceles does not significantly improve sperm motility (40). This may be explained in that higher-grade varicoceles are seemed to be the real pathology behind Asthenospermia, while low-grade and subclinical varicoceles maybe not be involved in this pathology. Nevertheless, some studies, such as that done by, recommended surgical treatment as the best option for the management of subclinical varicoceles. In our study, in spite of the low response of subclinical varicoceles to both types of treatment, the improvement in motility after varicolectomy was relatively better than after L-carnitine supplementation.

4. CONCLUSION

- Dignostic workup for infertile patients with Asthenospermia may reveal an overt cause for this problem, but a good proportion of patients have no clear identifiable cause.
- Best results of treatment are usually achieved when the treatment is directed to an overt cause.
- patients with Asthenospermia and clinically detected varicoceles are best treated by varicolectomy, and the more the grade of varicoceles, the better results achieved.
- L-carnitine supplementation for patients with Asthenospermia proved to be beneficial and safe, but when given alone, it was not enough to raise motility status to normal values.
- for patients with Asthenospermia and subclinical varicoceles, an efficient treatment still needs to be addressed because the two treatment modalities (varicolectomy and L-carnitine) tested in our study were not so effective.

Acknowledgments

The authors have no specific acknowledgments to make for this research.

Funding Information

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions Statement

Name of Author	C	M	So	Va	Fo	I	R	D	O	E	Vi	Su	P	Fu
Dr. Nafea Taha Salih	✓	✓	✓	✓		✓		✓	✓	✓	✓			
Dr. Gailan Adil Saeed	✓		✓	✓	✓			✓	✓			✓	✓	

C : Conceptualization

M : Methodology

So : Software

Va : Validation

Fo : Formal analysis

I : Investigation

R : Resources

D : Data Curation

O : Writing - Original Draft

E : Writing - Review & Editing

Vi : Visualization

Su : Supervision

P : Project administration

Fu : Funding acquisition

Conflict of Interest Statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Informed Consent

All participants were informed about the purpose of the study, and their voluntary consent was obtained prior to data collection.

Ethical Approval

Not Applicable.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.


REFERENCES


- [1] 'Practice Committee of American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss', Fertil Steril, vol. 90, no. 5, Nov. 2008. doi.org/10.1016/j.fertnstert.2008.08.065
- [2] K. W. Shih, P. Y. Shen, C. C. Wu, and Y. N. Kang, 'Testicular versus percutaneous epididymal sperm aspiration for patients with obstructive azoospermia: a systematic review and meta-analysis', Transl Androl Urol, vol. 8, no. 6, pp. 631-640, Dec. 2019. doi.org/10.21037/tau.2019.11.20
- [3] B. R. Winters and T. J. Walsh, 'The epidemiology of male infertility', Urol Clin North Am, vol. 41, no. 1, pp. 195-204, Feb. 2014. doi.org/10.1016/j.ucl.2013.08.006
- [4] S. Barak et al., 'Clinical Management of Male Infertility', In, Feb. 2016. doi.org/10.1016/B978-0-323-18907-1.00141-4
- [5] W. Cates, T. M. Farley, and P. J. Rowe, 'Worldwide patterns of infertility: is Africa different?', Lancet, vol. 2, no. 8455, pp. 596-598, Sept. 1985. [doi.org/10.1016/S0140-6736\(85\)90594-X](https://doi.org/10.1016/S0140-6736(85)90594-X)
- [6] S. C. Esteves, R. Miyaoka, and A. Agarwal, 'An update on the clinical assessment of the infertile male', Clinics (Sao Paulo), vol. 66, no. 4, pp. 691-700, 2011. doi.org/10.1590/S1807-59322011000400026
- [7] Evers JL. Female subfertility. Lancet. 2002 Jul 13;360 (9327):151-9. [doi.org/10.1016/S0140-6736\(02\)09417-5](https://doi.org/10.1016/S0140-6736(02)09417-5)

- [8] A. Jungwirth et al., 'European Association of Urology Working Group on Male Infertility. European Association of Urology guidelines on Male Infertility: the 2012 update', Eur Urol, vol. 62, no. 2, pp. 324-332, Aug. 2012. doi.org/10.1016/j.eururo.2012.04.048
- [9] A. Agarwal, A. Mulgund, A. Hamada, and M. R. Chyatte, 'A unique view on male infertility around the globe', Reprod Biol Endocrinol, vol. 13, Apr. 2015. doi.org/10.1186/s12958-015-0032-1
- [10] M. Sigman and J. P. Md, 'MD; Male Infertility', in Campbell-Walsh Urology, vol. 19, pp. 622-623, 2007.
- [11] T. Jungwirth and A. Diemer, 'Assisted Reproductive Technology Success Rate: National Summary and Fertility Clinic Reports', In European Association Of Urology, vol. 12, pp. 533-534, 2002.
- [12] P. Sengupta, S. Dutta, and E. Krajewska-Kulak, 'The Disappearing Sperms: Analysis of Reports Published Between 1980 and 2015', Am J Mens Health, vol. 11, no. 4, pp. 1279-1304, 1980. doi.org/10.1177/1557988316643383
- [13] Z. Veznik, L. Pospisil, D. Svecova, A. Zajicova, and V. Unzeitig, 'Chlamydiae in the ejaculate: their influence on the quality and morphology of sperm', Acta Obstet Gynecol Scand, vol. 83, pp. 656-660, 2004. doi.org/10.1080/j.0001-6349.2004.00542.x
- [14] 'Male infertility Best Practice Policy Committee of the American Urological Association; Practice Committee of the American Society For Reproductive Medicine', Report on varicocele and infertility. Fertil Steril, vol. 82, pp. 142-145, 2004.
- [15] L. Keskes-Ammar, N. Feki-Chakroun, T. Rebai, Z. Sahnoun, H. Ghazzi, and S. Hammami, 'Sperm oxidative stress and the effect of an oral vitamin E and selenium supplement on semen quality in infertile men', Arch Androl, vol. 49, pp. 83-94, 2003. doi.org/10.1080/01485010390129269
- [16] A. Lenzi, F. Lombardo, P. Sgrò, P. Salacone, L. Caponnetchia, and F. Dondero, 'Use of carnitine therapy in selected cases of male factor infertility: a double-blind cross over trial', Fertil Steril, vol. 79, pp. 292-300, 2003. [doi.org/10.1016/S0015-0282\(02\)04679-4](https://doi.org/10.1016/S0015-0282(02)04679-4)
- [17] G. Vitali, R. Parente, and C. Melotti, 'Carnitine supplementation in human idiopathic asthenospermia: clinical results', Drugs Exptl Clin Res, vol. 4, pp. 157-159, 1995.
- [18] G. Cavallini, A. P. Ferraretti, L. Gianaroli, G. Biagiotti, and G. Vitali, 'Cinnocicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia', J Androl, vol. 25, pp. 761-770, 2004. doi.org/10.1002/j.1939-4640.2004.tb02853.x
- [19] A. Lenzi, P. Sgrò, P. Salacone, D. Paoli, B. Gilio, and F. Lombardo, 'A placebo-controlled double-blind, randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia', Fertil Steril, vol. 81, pp. 1578-1584, 2004. doi.org/10.1016/j.fertnstert.2003.10.034

How to Cite: Dr. Nafea Taha Salih, Dr. Gailan Adil Saeed. (2023). Evaluation of treatment modalities for pure asthenospermia regarding changes in seminal fluid parameters. Journal Healthcare Treatment Development (JHTD), 3(2), 22–31. <https://doi.org/10.55529/jhtd.34.22.31>

BIOGRAPHIES OF AUTHORS

	Dr. Nafea Taha Salih, is a board-certified urological surgeon based in Kirkuk, Iraq. He holds an M.B.Ch.B. degree along with the prestigious Fellowship of the Iraqi Commission for Medical Specializations (F.I.C.M.S.) in Urology. Currently practicing under the Iraqi Ministry of Health, Kirkuk Health Directorate, he serves as a specialist urologist at Kirkuk Teaching Hospital. His work reflects a dedication to advancing urological care and surgical services for patients across the Kirkuk governorate in Iraq. Email: Nafeataha0@gmail.com
---	---



Dr. Gailan Adil Saeed, is a qualified urological surgeon practicing in Kirkuk, Iraq. He holds an M.B.Ch.B. degree and the Fellowship of the Iraqi Commission for Medical Specializations (F.I.C.M.S.) in Urology, representing one of Iraq's highest medical specialty credentials. Affiliated with the Iraqi Ministry of Health, Kirkuk Health Directorate, he serves as a specialist urologist at Azadi Teaching Hospital in Kirkuk. Dr. Saeed is committed to delivering advanced urological care and contributing to the development of surgical medical services within the Kirkuk governorate. Email: drgailanadil1977@yahoo.com